Precipio Clears $7 Million and Turns EBITDA Positive

Precipio Inc. (PRPO) told investors on its fiscal second-quarter 2026 earnings call that quarterly revenue surpassed $7 million, a company record, alongside positive adjusted EBITDA and strong operating cash flow; the shares last traded at 30.45, up 3.47% on the day.

Precipio Inc. (PRPO) used its fiscal second-quarter 2026 earnings call to mark the moment small-cap diagnostics investors wait years for: revenue above $7 million for the quarter, a company record, paired with positive adjusted EBITDA and cash generated from operations. Management framed the combination as a turning point rather than a one-quarter aberration.

The three data points matter in sequence, and each one carries a different weight. Record revenue says the commercial engine is working. Positive adjusted EBITDA says the revenue is arriving faster than the cost base is expanding. Operating cash flow says the earnings are not simply an accounting construct. For a company of this size, the third item is the one that changes the conversation with lenders, partners and prospective institutional holders.

Why crossing $7 million is the number that counts

Diagnostics laboratories are fixed-cost businesses. Instruments, accreditation, pathologist time and laboratory space have to be paid for whether the specimen volume shows up or not. That structure produces a threshold effect: below a certain revenue level a lab burns cash on every reporting cycle, and above it each incremental test drops a disproportionate share of its price to the bottom line.

Precipio's disclosure that quarterly revenue surpassed $7 million, coupled with a swing to positive adjusted EBITDA in the same period, is consistent with the company having crossed that threshold. Adjusted EBITDA — earnings before interest, tax, depreciation and amortization, with certain non-cash or non-recurring items stripped out — is not a substitute for net income, and investors should not treat it as one. But it is the metric that most directly captures whether the core operating business covers its own running costs, which is precisely the question that has hung over the name.

Held flat, a quarter above $7 million implies an annualized run-rate above $28 million on simple arithmetic. That figure is illustrative rather than guidance: it assumes no seasonality, no further volume growth and no reimbursement changes, none of which is a safe assumption in clinical diagnostics. The point of the calculation is scale, not forecast — it places Precipio in a revenue band where fixed-cost leverage starts working in the shareholder's favour rather than against it.

The cash-flow line is the credibility test

Plenty of micro-cap healthcare companies report an adjusted profit metric while still consuming cash. The gap usually sits in working capital, and in laboratory services it sits specifically in receivables. Diagnostics revenue is billed to commercial insurers, government payers and hospital clients, and the interval between running a test and being paid for it can be long. Revenue growth that outruns collections turns a profitable-looking quarter into a cash drain.

Precipio's statement that the quarter produced strong operating cash flow alongside the record top line suggests collections kept pace. That is the detail worth carrying forward into the next reporting period. If cash conversion holds while revenue continues to build, the company has demonstrated something structural. If a future quarter shows revenue up and operating cash flow back below zero, the receivables cycle — not demand — will be the explanation to interrogate.

Details of the call were reported by GuruFocus.

How the shares responded

PRPO last traded at 30.45, up 3.47% from the prior close of 29.43. The session range ran from 27.00 to 30.45, meaning the stock finished the day at the top of its range — a pattern that typically indicates buyers were still in control into the close rather than fading an early pop.

The move sat well ahead of the broad market. The S&P 500 tracker (SPY) closed at $765.72, up 0.41%, the Nasdaq 100 tracker (QQQ) at $713.44, up 0.35%, and the Dow tracker (DIA) at $532.22, up 0.89%, all as of the last trade at 20:00 GMT on 21 August 2026. In other words, roughly a fifth of a percent of index-level drift and several percent of company-specific reaction — the split you would expect when a thinly followed name delivers a result the market had not fully priced.

The intraday spread is itself informative. A gap between the day's low and the closing print of that width, in a stock this size, points to limited depth in the order book. Investors should expect two-way volatility of similar magnitude on modest volume, in both directions.

What has to hold for the turning point to stick

Three things determine whether this quarter reads as an inflection or a high-water mark.

• Revenue durability. Was the record driven by recurring test volume and a broader customer base, or by a concentrated order or timing benefit that will not repeat? Sequential growth in the next quarter answers it.
• Operating leverage. Positive adjusted EBITDA at this revenue level should widen as volume grows, provided headcount and laboratory capacity do not step up in lockstep. Watch whether cost growth stays below revenue growth.
• Reimbursement. Diagnostics pricing is set largely by payers, not by the lab. Coverage decisions and rate schedules can move realized revenue per test without any change in demand.

There is also the question of what management does with the cash. A company that has just started generating operating cash flow has options it did not have before: fund growth internally, reduce reliance on dilutive equity issuance, or invest ahead of demand. For long-suffering holders of small-cap diagnostics names, the end of routine share issuance is often worth more than the earnings line itself.

The next scheduled catalyst is the following quarter's report. Until then, the case rests on a single period in which revenue, profitability on an adjusted basis and cash generation all pointed the same way for the first time — a genuinely rare alignment at this scale, and one that has to be repeated before it can be called a trend.

Key facts

• Quarterly revenue: Surpassed $7 million — a company record (Q2 FY2026)
• Profitability milestone: Positive adjusted EBITDA, alongside strong operating cash flow
• PRPO last price: 30.45, +3.47% vs prior close of 29.43, as of 21 Aug 2026, 20:00 GMT
• Session range: 27.00 – 30.45; closed at the day's high

Frequently asked questions

What did Precipio report for its second quarter of fiscal 2026?

On its Q2 2026 earnings call, Precipio said quarterly revenue surpassed $7 million, a company record, and that it achieved positive adjusted EBITDA while generating strong operating cash flow. The company characterized the combination of record revenue, adjusted profitability and cash generation as a turning point for the business.

What does positive adjusted EBITDA actually mean here?

Adjusted EBITDA is earnings before interest, tax, depreciation and amortization, with certain non-cash or non-recurring items excluded. Turning positive means the core operating business covered its running costs during the quarter. It is not the same as net profit, which still includes interest, tax and non-cash charges that adjusted EBITDA leaves out.

How did PRPO shares perform?

PRPO last traded at 30.45, up 3.47% from the previous close of 29.43. The session range ran from 27.00 to 30.45, so the stock finished at the top of its intraday range. That gain was well ahead of the broad market indices, which each closed up under 1% on the same session.

Why does operating cash flow matter more than the revenue record?

Diagnostics companies bill insurers, government payers and hospitals, and payment can lag testing by months. A company can report record revenue and still consume cash if receivables build faster than collections. Reporting strong operating cash flow in the same quarter as record revenue suggests collections kept pace with billing.

Is the $7 million quarterly revenue level sustainable?

That is the open question. Precipio has reported one quarter at the record level. Whether it holds depends on recurring test volume, the breadth of the customer base and payer reimbursement rates, which the lab does not control. Sequential growth in the next reporting period would be the clearest evidence the level is durable.

What should investors watch next from Precipio?

Three items: whether revenue grows sequentially rather than plateauing, whether cost growth stays below revenue growth so adjusted EBITDA widens, and whether operating cash flow stays positive. Beyond that, any reduction in reliance on dilutive equity issuance would be a meaningful signal for existing shareholders.

Sources

• Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ... — GuruFocus

Photo: Edward Jenner · Pexels Licence — source